# Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

> **NCT02635061** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 17 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** ACY-241
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02635061
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-25
- **Primary completion:** 2024-01-22
- **Final completion:** 2024-01-22
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635061, "Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02635061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*